Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Schliemann

Showing results (381-390 of 427) with videos related to

Pageof 43
Sort By:
Nature Communications|January 19, 2021
Adrenomedullin-CALCRL axis controls relapse-initiating drug tolerant acute myeloid leukemia cellsClément Larrue, Nathan Guiraud, Pierre-Luc Mouchel, et al.
Contact Dermatitis|July 1, 2016
A variant of the CXCL11 gene may influence susceptibility to contact allergy, particularly in polysensitized patientsGötz A Westphal, Hans-Peter Rihs, Antje Schaffranek, et al.
Leukemia & Lymphoma|January 5, 2021
Decitabine treatment in 311 patients with acute myeloid leukemia: outcome and impact of <i>TP53</i> mutations - a registry based analysisJan M Middeke, Raphael Teipel, Christoph Röllig, et al.
JAMA Oncology|February 9, 2023
Allogeneic Hematopoietic Cell Transplantation vs Standard Consolidation Chemotherapy in Patients With Intermediate-Risk Acute Myeloid Leukemia: A Randomized Clinical TrialMartin Bornhäuser, Christoph Schliemann, Johannes Schetelig, et al.
Journal of Hematology & Oncology|December 2, 2022
Electrostatic anti-CD33-antibody-protamine nanocarriers as platform for a targeted treatment of acute myeloid leukemiaNicole Bäumer, Annika Scheller, Lisa Wittmann, et al.
Nature Medicine|December 20, 2016
SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemiaConstanze Schneider, Thomas Oellerich, Hanna-Mari Baldauf, et al.
Cancers|June 11, 2020
First-In-Class CD13-Targeted Tissue Factor tTF-NGR in Patients with Recurrent or Refractory Malignant Tumors: Results of a Phase I Dose-Escalation StudyChristoph Schliemann, Mirjam Gerwing, Hauke Heinzow, et al.
Blood|January 15, 2025
Common hereditary variants of the APOE gene and posttransplant outcome in acute myeloid leukemiaJulian Ronnacker, Michael Grau, Maximilian Klasmeier, et al.
Scientific Reports|February 19, 2026
Trabectedin plus CD13-targeted tissue factor tTF-NGR against advanced relapsed or refractory soft tissue sarcoma: translational data, clinical safety and efficacyKathrin Hessling, Caroline Brand, Christian Schwöppe, et al.
Cell Stem Cell|April 25, 2023
Clonally resolved single-cell multi-omics identifies routes of cellular differentiation in acute myeloid leukemiaSergi Beneyto-Calabuig, Anne Kathrin Merbach, Jonas-Alexander Kniffka, et al.
Pageof 43

Showing results (381-390 of 427) with videos related to

Sort By:
Pageof 43
Nature Communications|January 19, 2021
Adrenomedullin-CALCRL axis controls relapse-initiating drug tolerant acute myeloid leukemia cellsClément Larrue, Nathan Guiraud, Pierre-Luc Mouchel, et al.
Contact Dermatitis|July 1, 2016
A variant of the CXCL11 gene may influence susceptibility to contact allergy, particularly in polysensitized patientsGötz A Westphal, Hans-Peter Rihs, Antje Schaffranek, et al.
Leukemia & Lymphoma|January 5, 2021
Decitabine treatment in 311 patients with acute myeloid leukemia: outcome and impact of <i>TP53</i> mutations - a registry based analysisJan M Middeke, Raphael Teipel, Christoph Röllig, et al.
JAMA Oncology|February 9, 2023
Allogeneic Hematopoietic Cell Transplantation vs Standard Consolidation Chemotherapy in Patients With Intermediate-Risk Acute Myeloid Leukemia: A Randomized Clinical TrialMartin Bornhäuser, Christoph Schliemann, Johannes Schetelig, et al.
Journal of Hematology & Oncology|December 2, 2022
Electrostatic anti-CD33-antibody-protamine nanocarriers as platform for a targeted treatment of acute myeloid leukemiaNicole Bäumer, Annika Scheller, Lisa Wittmann, et al.
Nature Medicine|December 20, 2016
SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemiaConstanze Schneider, Thomas Oellerich, Hanna-Mari Baldauf, et al.
Cancers|June 11, 2020
First-In-Class CD13-Targeted Tissue Factor tTF-NGR in Patients with Recurrent or Refractory Malignant Tumors: Results of a Phase I Dose-Escalation StudyChristoph Schliemann, Mirjam Gerwing, Hauke Heinzow, et al.
Blood|January 15, 2025
Common hereditary variants of the APOE gene and posttransplant outcome in acute myeloid leukemiaJulian Ronnacker, Michael Grau, Maximilian Klasmeier, et al.
Scientific Reports|February 19, 2026
Trabectedin plus CD13-targeted tissue factor tTF-NGR against advanced relapsed or refractory soft tissue sarcoma: translational data, clinical safety and efficacyKathrin Hessling, Caroline Brand, Christian Schwöppe, et al.
Cell Stem Cell|April 25, 2023
Clonally resolved single-cell multi-omics identifies routes of cellular differentiation in acute myeloid leukemiaSergi Beneyto-Calabuig, Anne Kathrin Merbach, Jonas-Alexander Kniffka, et al.
Pageof 43